You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

Here's the differences between the major credit card processors, and how to evaluate them as investments.

We try and decode what's going on with Twitter's DAU/MAU numbers, and run through the figures on another banner quarter for the world's largest company.

Years after the downturn started, oil majors relent and believe $50 oil is the new reality. Are they right?

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

We break down the latest developments in the consumer-retail sector, including Amazon earnings, the $1.4 billion Jimmy Choo buyout, and the turnaround prospects for Target.

Get $25 off your first purchase at http://bombfell.com/fool.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other?

Fossil fuels may be critical today, but that fact is changing at an accelerated rate.

Hunting for new small cap stocks to watch? We've got you covered. In today's show, we discuss how NovoCure, Flexion Therapeutics, and Zogenix want to shake-up healthcare.

Michael Kors scoops up Jimmy Choo to keep pace with Coach, and Lululemon's back after a spring mishap, could its winning days continue? We hit these retail news items and check in on Chipotle's food-borne illness problems ahead of earnings.

For years after the financial crisis, bank earnings fluctuated wildly due to high loan losses, volatile markets, and elevated legal expenses. Fortunately, this trend seems to have come to an end, as the results from the second quarter demonstrate.

Shopify and its founder Tobias Lütke have been Fool favorites for a long time -- on this episode we talk about how, despite the stock's crazy run over the past year, we're still interested in the e-commerce company.

Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool

OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices?

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We field Foolish questions from the world of consumer and retail. First, Levi wants to know about the prospects for apparel retailer Buckle (and its double-digit dividend yield). Meanwhile, Shubhra is curious about Kirkland Signature and why the Costco private label is available on Amazon.com.

Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set -- go to Harrys.com/fool.

Brian Patrick Eha, author of How Money Got Free, joins Gaby Lapera to discuss cryptocurrencies, tokens, blockchain technology, and what it all means for investors, regulators, and financial systems.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We love covering IPOs, but we can't bring ourselves to buy a stock that's only been publicly traded for a few months. We explain why on the final episode of "never will I ever week."

 We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them.

Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.

We continue with our theme for this week, as Asit Sharma explains the major hurdles day traders and speculators face in their pursuit of easy profits.

In this episode of Industry Focus: Financials, we dig into things we'd never do -- or, at least, that we try to avoid. This includes investing advice, as well as pointers about life more generally.

Looking for a beach read or a podcast to pass the time on the family trip? We run through some of our favorite tech books and shows so you can still get your fix during the slow months of summer.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

Is being late better than never arriving for America's biggest oil major?

After Walgreens' abandoned plans to buy it lock-stock-and-barrel, Rite Aid shares are crashing. Does this give Amazon.com the moment it's been waiting for to disrupt the prescription drug market?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

There's no one, right answer, but getting a job while in school can help teach a lot of important things. Tune in to find out what Motley Fool contributors Dan Kline and Gaby Lapera think you ought to know.

In the past month, Pandora has sold off Ticketfly, announced a large investment stake from Sirius, and had its CEO step down. What should investors make of the shake-up? Plus we check in on Apple Music and Tesla's puzzling streaming music ambitions.

Solar stocks are finaly rallying after a year of malaise, is this the long-rumored revound?

The Congressional Budget Office announces a discouraging outlook for Trumpcare. And Portola Pharmaceuticals’ shares increase more in one day than they cost last November.

After spending several months covering casualties, headwinds, and consolidation in the retail sector, we turn our attention to two companies that have thrived in the era of e-commerce. Ulta Beauty and TJX Companies are growing thanks to their physical store footprints, not in spite of them.

Credit ratings agencies (CRAs) have the power to move markets, and decide the fortunes of publicly-traded companies around the world.

What doesn't MercadoLibre do? Today we talk about the Amazon/eBay/Craigslist/PayPal of Latin America, what's been fueling its impressive growth, and some of the things investors need to keep in mind if they're considering buying in.

Thanks to Thumbtack for supporting Motley Fool (thumbtack.com).

There’s lots of ways to move goods and people in today’s economy, but which option is the most economical?

AbbVie is developing new drugs to sidestep expiring patents on its best-seller, and a new FDA approval could be on deck at Clovis Oncology. Also, how Novartis plans to shake-up a multibillion dollar indication.

he grocery industry is bracing itself for further disruption as e-commerce giant Amazon announced a surprise buyout of Whole Foods Market. Meanwhile, the Nordstrom family is weighing their options for taking the department store private.

Thanks to Thumbtack for supporting the Motley Fool.  Hire local, skilled pros for just about anything at thumbtack.com today.

If you're a recent graduate, congratulations! Here's what you need to know about your money.

Apple is one of the most bet against stocks in the market... kind of. We explain why it's true, but kind of a misleading stat.

GE’s CEO may have just retired, but he left the company perfectly positioned for a green-energy fueled future.

A Supreme Court decision that speeds biosimilar drugs to market makes investing in biosimilar stocks even more enticing.  

Discount supermarket chain Aldi will be investing billions in the U.S. market over the next five years, while its fellow German-based rival Lidl prepares to open its first U.S. locations this week. But the biggest winner from this growing competition will be the U.S. consumer.

The House of Representatives voted last week in favor of the Financial CHOICE Act, which is designed to roll back the enhanced regulatory regime laid out in the Dodd-Frank Act of 2010. On this episode of Industry Focus, we dig into the Financial CHOICE Act and discuss what this means for banks.

The average investor has a wealth of information at their fingertips, they just need to know where to find it. We talk about our favorite free tools and resources, and Michael Douglass explains why he thinks "the numbers obscure the true story."

Railroad stocks have consistently beaten the market – here’s why investors should give them a look today.

Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week.

Sponsored link: http://www.casper.com/fool code fool.

In its last private funding round, Blue Apron reached a valuation of over $2 billion. Now, the company has its sights set on the public market, and we are digging into the IPO filing to break down the financials and business model of meal kit delivery for investors.

Citizens Financial became the biggest bank stock IPO in history when it went public in 2014. Since then, it's orchestrated an impressive turnaround.

Sponsored link: http://www.casper.com/fool code fool.

Last week we showered Activision, Take-Two, and EA with love, but what about pure-play mobile game publishers like Zynga and Glu Mobile? Do they deserve a spot on your watch list?

Thanks to Bombfell for supporting The Motley Fool.  Get $25 off your first purchase at http://bombfell.com/fool

Donald Trump is likely to pull the US out of the Paris Climate Agreement – here’s what it means.

Thanks to Bombfell for supporting The Motley Fool.  Get $25 off your first purchase at http://bombfell.com/fool

Summer may not be the best time to own stocks historically, but embracing this old Wall Street adage is far from risk-less.

We look at major acquisition talks making headlines this week as American Eagle pursues its apparel rival Abercrombie & Fitch, and Kraft-Heinz eyes a mega-deal with Colgate-Palmolive.

Have you ever wondered what the Industry Focus cast is like in real life? This episode gives you a glimpse.

Game publishers Activision, Take-Two, and Electronic Arts have all soared so far in 2017. With all three up over 40% year-to-date, is it too late for investors to hop in and play?

OPEC extended its production cut for another 9 months, could this be a desperate move by a powerless cartel?

Extreme birth defects associated with a popular anti-anxiety medicine from the 1960's had a lasting impact on today's healthcare policy -- and the drug is still a major part of Celgene's cancer portfolio.

From McDonald’s “Experience of the Future” to Panera 2.0, the restaurant industry is investing heavily in technology as a means of reducing costs and improving the dining experience. Find out how different companies are approaching the automation and customer demands that loom over the horizon.

oin us for a primer on how the insurance industry works, how insurers make money, and how to evaluate insurance stocks for potential investment opportunities.

Twilio and Yelp are each down over 20% following earnings, are the drops signs of trouble or buying opportunities for investors?

Saudi Arabia and Russia desperately want oil back to its highs – but just how likely is it?

We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust.

Thanks to Slack for supporting The Motley Fool.  Learn more at slack.com.

A flurry of earnings reports from Macy’s, Nordstrom, and other department stores were greeted by bearish investors as shares declined as much as 20%. We drill down into the results before considering the longer term outlook for this industry.

Bitcoin might be the future. If you really want to understand it, you need to look at its past. Brian Patrick Eha's _How Money Got Free: Bitcoin and the Fight for the Future of Finance_ gives you the background you need to think about Bitcoin today.
Intro: Bitcoin. It's interesting, it's powerful, and it's confusing to most people. Luckily, Brian Patrick Eha has written a beautiful history and analysis of bitcoin. Join the Motley Fool's Gaby Lapera as she interviews Mr. Eha about his new book, _How Money Got Free: Bitcoin and the Fight for the Future of Finance_.

Snap's first quarter of financial results are out, and the numbers... weren't so great. We sort through the report, and dig into the details we didn't get in the company's original prospectus.

Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set – go to Harrys.com/fool

The oil & gas sector’s first quarter results are out, and the managements of these huge companies have made some interesting capital decisions.

With the $2.4 billion acquisition of Kate Spade, Coach hopes to reach millennial shoppers with a popular brand that it can eventually expand to new markets abroad. Meanwhile, Comcast and Charter team up to tackle the wireless industry.

Thanks to Harry’s for supporting the Motley Fool. To get your free trial set -- go to Harrys.com/fool

Motley Fool analyst Michael Douglass joins analyst Gaby Lapera to discuss key takeaways from this year's Berkshire Hathaway annual meeting.

Our favorite show of the quarter, Apple earnings! Plus what's up with WhatsApp and Facebook's other properties AND the final clues for puzzle week!

Oil has continued its drop in spite of OPEC’s promises to keep production low: What’s an investor to do?

Winners and losers can teach us valuable lessons about what's important -- and not important -- when it comes to investing.

Thanks to Slack for supporting The Motley Fool.  Learn more at www.slack.com

As the No. 2 name worldwide in sports apparel, Adidas deserves some extra attention from investors, especially as it continues to deliver industry-leading growth. With shares up nearly 200% in the past two years, here is what you need to know about the first major brand in sports.

What does the future of banking look like? That question is at the top of bankers' minds today. In this episode of Industry Focus: Financials, The Motley Fool's Gaby Lapera and John Maxfield discuss new technologies that are shaping the way banks serve customers.

Thanks to Slack for supporting The Motley Fool.  Learn more at www.slack.com

Twitter beat guidance and showed strong MAU growth in its most recent quarter, is it enough to start talking about a turnaround? Plus we hit Amazon's awesome earnings release.

Bad news for oil producers, great news for oil pipeline operators.

Missteps on repeal-and-replace mean business as usual for insurers, and first quarter results suggest that's a good thing. Also, Fresenius acquires Akorn, and Express Scripts' ongoing battle with Anthem "gets real".

Terrible fourth-quarter results, a slew of store closures, and bankruptcies have led to the perception that brick-and-mortar retail is experiencing a slow death, but opportunities abound for retailers willing to adapt and evolve.

The market looks at alternative asset managers and sees complexity, but some investors may see opportunity.

Answering a listener question, we talk about how hard it is to time the market, and why it's better for investors to ride out the waves and dollar-cost average.

Thanks to Warby Parker for supporting Motley Fool.  Order your FREE Home Try-On’s at http://www.warbyparker.com/fool

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

After releasing its first quarter financials, J&J's stock fell over 3%. Is it a buy? In this episode, we dig into the quarter's highlights and low-lights to find out.

After seeing gambling revenue tumble 40% over two harrowing years, casino operators in Macau are breathing a sigh of relief as new, integrated resorts restore some growth to the region. With a massive new market also on the horizon, this will be an important industry to watch over the next several years.

Three of the nation's biggest banks reported first-quarter earnings last week. We discuss the results (and then some) in this week's episode of Industry Focus: Financials.

Thanks to Warby Parker for supporting Motley Fool. Order your FREE Home Try-On’s at http://www.warbyparker.com/fool

Russia loaned Venezuela’s state oil company, which owns CITCO, a lot of money – now they want to be paid back.

Deaths due to prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.

In the past year, we have discussed the management shake-up at Viacom, as well as the $5.5 billion merger between Cabela’s and Bass Pro Shops. Both companies have hit roadblocks with their plans -- here is what you need to know.

With the April 18 tax filing deadline fast approaching, here are some things you need to know.

The average investor doesn't have a shot at buying shares of an IPO at issuance price... but that could be changing soon. ClickIPO's CEO Scott Coyle hops on the show to talk about the IPO market, and how his company is hoping to democratize access to IPO's and secondary issuances.

Oil prices are in limbo -- here's what the bulls have to say.

We all have cognitive biases, but if we're not careful, they can lead to bad investments. In this episode, we investigate the relationship between psychology and investing, and explain how you can outsmart your biases.

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool

We look at recent quotes from the management teams at Target and Dr. Pepper Snapple to determine whether their hopeful plans for the future should be accepted at face value by investors. In other news, Panera Bread hit a fresh all-time high Monday after news broke that the company is fielding buyout offers -- here are the companies likely to pursue a deal.

Over the past two decades, PNC Financial has evolved into one of the best-managed companies in the financial services sector. Listen in as The Motley Fool's Gaby Lapera and John Maxfield dissect what's behind its success.

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool

Snap got a bump early this week as a flurry of "Buy" notes came in from sell-side analysts. On this episode, we walk through the sell-side/buy-side dynamic and dig into the analyst reports.

In a classic case of whiplash, hedge funds are now turning sour on crude after bullish bets hit an all-time high just a few weeks ago – the Energy crew weighs in.

Thanks to Audible for supporting our podcast. Listen to Audible’s new original seires: Ponzi Supernove. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

A jam-packed month for news that includes a failed plan to replace Obamacare, a big cardiovascular study, a fast-approaching IPO, and a big advance in treating ovarian cancer has big implications on top healthcare stocks.

With billions of gamers and technology improving each year, video game companies are finding new ways to engage with customers. Here are some of the major takeaways for investors.

You asked for it! Motley Fool Options analyst JP Bennett hops on the show to do an introduction to options and answer some listener questions on the topic. 

Thanks to Audible for supporting our podcast. Listen to Audible’s new original series: Ponzi Supernova. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

Oil prices are up, but not anywhere near where their highs of 2014 – so why are producers upping production by 1 million barrel?

Veeva's President discusses the cloud solution company he co-founded, from its small beginnings in healthcare CRM to its latest Vault products and expansion outside of life sciences.

Asit Sharma joins the show to help answer questions from our Foolish listeners who want to know more about goodwill and the $300 billion food distribution industry.

Thanks to Audible for supporting our podcast. Listen to Audible’s new original series: Ponzi Supernova. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

Not every legendary investor is worth following, and not every way to get rich is as obvious as it may seem.